PATH · Company research
UiPath, Inc. (PATH): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
27records availableTechnology
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Marvell Investor Day: MRVL Stock Rockets As Firm Lays Out Path To Up To $90B In Annual Revenue By Fiscal 2031 - Stocktwits | Marvell Investor Day: MRVL Stock Rockets As Firm Lays Out Path To Up To $90B In Annual Revenue By Fiscal 2031 Stocktwits | View source ↗ | Stocktwits | Oct 18, 2026 | neutral | 0 | 0.6 |
| UiPath Stock Gets Oracle Marketplace Listing For Test Cloud - Simply Wall Street | UiPath Stock Gets Oracle Marketplace Listing For Test Cloud Simply Wall Street | View source ↗ | Simply Wall Street | Oct 17, 2026 | neutral | 0 | 0.6 |
| PATH Stock Slips As Wall Street Slashes Price Targets - StocksToTrade | PATH Stock Slips As Wall Street Slashes Price Targets StocksToTrade | View source ↗ | StocksToTrade | Oct 16, 2026 | neutral | 0 | 0.6 |
| UiPath, Inc. (PATH) Stock Forecasts - Yahoo Finance | UiPath, Inc. (PATH) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 14, 2026 | neutral | 0 | 0.6 |
| UiPath (PATH) Dips More Than Broader Market: What You Should Know | UiPath (PATH) declined 1.43% to $13.06 in the latest session, underperforming the S&P 500's 1.11% loss. Despite a 6.89% monthly drop, the company maintains a Zacks Rank #2 (Buy) rating with positive earnings revisions. Analysts project Q earnings of $0.19 per share (+18.75% YoY) and full-year revenue of $1.79 billion (+11.25% YoY). The stock trades at a Forward P/E of 16.7, below its industry average of 20.8. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 1 | 1 |
| UiPath (NYSE:PATH) Stock: Insider Brad Brubaker Sells 27,404 Shares - MarketBeat | UiPath (NYSE:PATH) Stock: Insider Brad Brubaker Sells 27,404 Shares MarketBeat | View source ↗ | MarketBeat | Oct 13, 2026 | neutral | 0 | 0.6 |
| A planned 27,404-share sale leaves UiPath (PATH) legal chief with 1,066,107 directly held shares. - Stock Titan | A planned 27,404-share sale leaves UiPath (PATH) legal chief with 1,066,107 directly held shares. Stock Titan | View source ↗ | Stock Titan | Oct 13, 2026 | neutral | 0 | 0.6 |
| After selling 29,564 shares, UiPath (PATH) CTO Malpani holds 1,514,281 shares directly. - Stock Titan | After selling 29,564 shares, UiPath (PATH) CTO Malpani holds 1,514,281 shares directly. Stock Titan | View source ↗ | Stock Titan | Oct 13, 2026 | neutral | 0 | 0.6 |
| UiPath Stock Gains 33% in 6 Months: Should You Buy, Hold or Fold? | UiPath (PATH) has gained 33% over six months, driven by expanding AI capabilities through its Maestro platform and improving profitability. Q2 revenues rose 13% to $410M with ARR climbing 12% to $1.94B. Trading at a forward P/E of 15.29 versus the industry average of 30.92, PATH appears undervalued. However, intensifying competition and uncertain enterprise spending pose risks to growth. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.333 | 1 |
| UiPath Stock Gains 33% in 6 Months: Should You Buy, Hold or Fold? | UiPath (PATH) has gained 33% over six months, driven by expanding AI capabilities through its Maestro platform and improving profitability. Q2 revenues rose 13% to $410M with ARR climbing 12% to $1.94B. Trading at a forward P/E of 15.29 versus the industry average of 30.92, PATH appears undervalued. However, intensifying competition and uncertain enterprise spending pose risks to growth. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.333 | 1 |
| A software stock offering a clear path to growth - Investors' Chronicle | A software stock offering a clear path to growth Investors' Chronicle | View source ↗ | Investors' Chronicle | Oct 13, 2026 | neutral | 0 | 0.6 |
| Satellogic: A Promising Path If Management's Vision Materializes - Seeking Alpha | Satellogic: A Promising Path If Management's Vision Materializes Seeking Alpha | View source ↗ | Seeking Alpha | Oct 13, 2026 | neutral | 0 | 0.6 |
| CAPR Stock Surges 67% After-Hours — Is There Still A Path Forward For Deramiocel? - Stocktwits | CAPR Stock Surges 67% After-Hours — Is There Still A Path Forward For Deramiocel? Stocktwits | View source ↗ | Stocktwits | Oct 13, 2026 | neutral | 0 | 0.6 |
| C3.ai vs. UiPath: Which AI-Driven Tech Stock Is a Better Buy in 2026? | The article compares C3.ai and UiPath as investments in the agentic AI automation space. UiPath is recommended as the better buy due to its profitability, positive free cash flow, and consistent growth trajectory. C3.ai, while showing recent improvements like positive free cash flow and 73% quarter-over-quarter booking growth, remains unprofitable with substantial net losses and is still in early restructuring stages under CEO Thomas Siebel. | View source ↗ | The Motley Fool | Oct 13, 2026 | bullish | 0.167 | 1 |
| UiPath, Inc. (PATH) Is a Trending Stock: Facts to Know Before Betting on It | UiPath (PATH) is a trending stock with a Zacks Rank #2 (Buy) rating. The company shows positive earnings momentum with current quarter EPS expected at $0.19 (+18.8% YoY) and fiscal year EPS of $0.79 (+9.7% YoY). Revenue growth is projected at 11.3% for the current fiscal year. The stock has underperformed the S&P 500 over the past month (-2% vs +2.4%) but trades at fair valuation relative to peers. | View source ↗ | Zacks Investment Research | Oct 12, 2026 | bullish | 1 | 1 |
| UiPath, Inc. (PATH) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance | UiPath, Inc. (PATH) Is a Trending Stock: Facts to Know Before Betting on It Yahoo Finance | View source ↗ | Yahoo Finance | Oct 12, 2026 | neutral | 0 | 0.6 |
| BIIB Stock: JPMorgan Sees ‘Increasingly Compelling Catalyst Path’ For Biogen, Raises Price Target To $300 - TradingView | BIIB Stock: JPMorgan Sees ‘Increasingly Compelling Catalyst Path’ For Biogen, Raises Price Target To $300 TradingView | View source ↗ | TradingView | Oct 12, 2026 | neutral | 0 | 0.6 |
| PATH 261016 12.00C (PATH261016C12000) Stock Options Chain | Quotes & News - Moomoo | PATH 261016 12.00C (PATH261016C12000) Stock Options Chain | Quotes & News Moomoo | View source ↗ | Moomoo | Oct 12, 2026 | neutral | 0 | 0.6 |
| UiPath (PATH) Wins Analyst Backing, Is The Stock Cheap? - Simply Wall Street | UiPath (PATH) Wins Analyst Backing, Is The Stock Cheap? Simply Wall Street | View source ↗ | Simply Wall Street | Oct 10, 2026 | neutral | 0 | 0.6 |
| UiPath Inc Share Price - PATH, RNS News, Articles, Quotes, & Charts (NYSE:PATH) - Proactive financial news | UiPath Inc Share Price - PATH, RNS News, Articles, Quotes, & Charts (NYSE:PATH) Proactive financial news | View source ↗ | Proactive financial news | Oct 10, 2026 | neutral | 0 | 0.6 |
| UiPath Inc. Stock Grades | PATH - Barron's | UiPath Inc. Stock Grades | PATH Barron's | View source ↗ | Barron's | Oct 9, 2026 | neutral | 0 | 0.6 |
| UiPath (PATH) Rises As Market Takes a Dip: Key Facts | UiPath (PATH) closed at $13.25, up 1.38%, outperforming the S&P 500's 0.47% decline. The enterprise automation software company is expected to report earnings of $0.19 per share with 18.75% year-over-year growth. With a Zacks Rank of #2 (Buy), a Forward P/E of 16.48 (below industry average of 20.39), and a PEG ratio of 0.76, UiPath appears undervalued. Consensus estimates forecast full-year earnings of $0.79 per share and revenue of $1.79 billion, representing 9.72% and 11.25% growth respectively. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 1 | 1 |
| UiPath (PATH) Rises As Market Takes a Dip: Key Facts | UiPath (PATH) closed at $13.25, up 1.38%, outperforming the S&P 500's 0.47% decline. The enterprise automation software company is expected to report earnings of $0.19 per share with 18.75% year-over-year growth. With a Zacks Rank of #2 (Buy), a Forward P/E of 16.48 (below industry average of 20.39), and a PEG ratio of 0.76, UiPath appears undervalued. Consensus estimates forecast full-year earnings of $0.79 per share and revenue of $1.79 billion, representing 9.72% and 11.25% growth respectively. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 1 | 1 |
| The Innovation Exemption Arrives: SEC Clears a Conditional Path for Onchain Trading of Tokenized NMS Stocks - WilmerHale | The Innovation Exemption Arrives: SEC Clears a Conditional Path for Onchain Trading of Tokenized NMS Stocks WilmerHale | View source ↗ | WilmerHale | Oct 5, 2026 | neutral | 0 | 0.6 |
| SEC Clears Path for On-Chain Trading of Tokenized Stocks With Landmark Innovation Exemption - https://www.fintechanddigitalassets.com/ | SEC Clears Path for On-Chain Trading of Tokenized Stocks With Landmark Innovation Exemption https://www.fintechanddigitalassets.com/ | View source ↗ | https://www.fintechanddigitalassets.com/ | Sep 29, 2026 | neutral | 0 | 0.6 |
| Why UiPath (PATH) Stock Is Down Today - Yahoo Finance | Why UiPath (PATH) Stock Is Down Today Yahoo Finance | View source ↗ | Yahoo Finance | Sep 24, 2026 | neutral | 0 | 0.6 |
| Why UiPath (PATH) Stock Is Down Today - StockStory | Why UiPath (PATH) Stock Is Down Today StockStory | View source ↗ | StockStory | Sep 24, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.